Arixil Vet 20 mg Film-coated Tablet for Dogs

In double-blind clinical trials in dogs with congestive heart failure, the veterinary
medicinal product was well tolerated with an incidence of adverse reactions in treated
dogs lower than that observed in placebo-treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of
fatigue.
In dogs with chronic kidney disease, the veterinary medicinal product may increase
plasma creatinine concentrations at the start of therapy. A moderate increase in
plasma creatinine concentrations following administration of ACE inhibitors is
compatible with the reduction in glomerular hypertension induced by these agents, and
is therefore not necessarily a reason to stop therapy in the absence of other signs.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).